The recent FDA approval of sarilumab for the treatment of refractory polymyalgia rheumatica may have a significant and lasting impact on the use of long-term steroids for that condition.
PHILADELPHIA — Patients with steroid-resistant polymyalgia rheumatica who received sarilumab and tapered glucocorticoids achieved higher remission rates vs. glucocorticoid taper alone, according to data presented at ACR Convergence 2022.
Relapsing patients treated with the biologic had significantly higher sustained remission and reported better quality of life, compared with the control group, in a randomized controlled trial.